ALK
Os inibidores de ALK são compostos que especificamente visam e inibem a quinase do linfoma anaplásico (ALK), uma tirosina quinase receptora envolvida no desenvolvimento e progressão de certos cânceres, incluindo o câncer de pulmão de células não pequenas e o neuroblastoma. Ao inibir ALK, esses compostos bloqueiam vias de sinalização que promovem o crescimento e a sobrevivência das células tumorais. Na CymitQuimica, oferecemos inibidores de ALK para apoiar sua pesquisa em oncologia, terapias direcionadas contra o câncer e transdução de sinal.
Foram encontrados 135 produtos de "ALK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Fórmula:C23H22ClFN6OPureza:99.71%Cor e Forma:SolidPeso molecular:452.91IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Fórmula:C25H20N6OPureza:99.79%Cor e Forma:SolidPeso molecular:420.47CEP-14083
CAS:CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.Fórmula:C31H30N6O2Cor e Forma:SolidPeso molecular:518.61TGF-βRI inhibitor 3
CAS:TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.
Fórmula:C21H21NO4Cor e Forma:SolidPeso molecular:351.396WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Fórmula:C33H45BrN8O5SCor e Forma:SolidPeso molecular:745.73ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Fórmula:C36H45N5O3Cor e Forma:SolidPeso molecular:595.77DDO-02267
CAS:DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.Fórmula:C18H12N2O7SCor e Forma:SolidPeso molecular:400.362PF-06463922 acetate
CAS:PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Fórmula:C23H23FN6O4Cor e Forma:SolidPeso molecular:466.46ALK-IN-23
ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.Fórmula:C26H29ClN8O3SCor e Forma:SolidPeso molecular:569.08CDD-1115
CAS:CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.Fórmula:C32H30N6O3Cor e Forma:SolidPeso molecular:546.619ALKBH5-IN-3
CAS:ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Fórmula:C11H7F3N2O3Pureza:98.32%Cor e Forma:SolidPeso molecular:272.18W23-1006
CAS:W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Fórmula:C17H12BrN3O5Cor e Forma:SolidPeso molecular:418.198DA-0157
CAS:DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Fórmula:C31H43BrN7O2PCor e Forma:SolidPeso molecular:656.597AZ12601011
CAS:AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.Fórmula:C19H15N5Pureza:98.81%Cor e Forma:SolidPeso molecular:313.36Ref: TM-T10426
1mg99,00€5mg235,00€10mg376,00€25mg728,00€50mg1.093,00€100mg1.510,00€1mL*10mM (DMSO)259,00€Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Fórmula:C21H20F3N5O3Pureza:98.7%Cor e Forma:SolidPeso molecular:447.41Ref: TM-T9414
1mg120,00€5mg283,00€10mg464,00€25mg929,00€50mg1.473,00€100mg1.977,00€200mg2.802,00€1mL*10mM (DMSO)319,00€
